, Volume 67, Issue 5, pp 685–700 | Cite as

Optimal Management Strategies for Chronic Iron Overload

Therapy In Practice


Iron overload is characterised by excessive iron deposition and consequent injury and dysfunction of target organs, especially the heart, liver, anterior pituitary, pancreas and joints. Iron overload disorders are common worldwide and occur in most major race/ethnicity groups. Physiological mechanisms to excrete iron are very limited. Thus, all patients with iron overload need safe and effective treatment that is compatible with their co-existing medical conditions. Treatments for iron overload include phlebotomy and erythrocytapheresis that remove iron predominantly as haemoglobin, and chelation therapy with drugs that bind excess iron selectively and increase its excretion. The most important potential benefits of therapy are preventing deaths due to cardiac siderosis and hepatic cirrhosis. Preventing iron-related injury to endocrine organs is critical in children. Successful treatment or prevention of iron overload increases quality of life and survival in many patients. This article characterises the major categories of iron overload disorders, tabulates methods to evaluate and treat iron overload, and describes treatment options for iron overload disorders. Research needed to advance knowledge about treatment of iron overload is proposed.



This work was supported in part by Southern Iron Disorders Center. The author’s work was independent of the funding source. The author has no conflicts of interest to declare.


  1. 1.
    Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239–52PubMedCrossRefGoogle Scholar
  2. 2.
    Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001, 47–61Google Scholar
  3. 3.
    Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319–24PubMedCrossRefGoogle Scholar
  4. 4.
    Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408PubMedCrossRefGoogle Scholar
  5. 5.
    Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program 2003, 40–61Google Scholar
  6. 6.
    Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa: interaction between a gene and dietary iron content. N Engl J Med 1992; 326: 95–100PubMedCrossRefGoogle Scholar
  7. 7.
    Barton JC, Acton RT, Rivers CA, et al. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. Blood Cells Mol Dis 2003; 31: 310–9PubMedCrossRefGoogle Scholar
  8. 8.
    Beutler E, Barton JC, Felitti VJ, et al. Ferroportin 1 (SCL40A1) variant associated with iron overload in African-Americans. Blood Cells Mol Dis 2003; 31: 305–9PubMedCrossRefGoogle Scholar
  9. 9.
    Jaeger M, Aul C, Sohngen D, et al. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes [in German]. Beitr Infusionsther 1992; 30: 464–8PubMedGoogle Scholar
  10. 10.
    Gattermann N. Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelators. Hematol Oncol Clin 2005; 19 Suppl. 1: 13–7Google Scholar
  11. 11.
    Vassiliadis T, Garipidou V, Perifanis V, et al. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006; 12: 818–21PubMedGoogle Scholar
  12. 12.
    Halpern Z, Rahmani R, Levo Y. Severe hemochromatosis: the predominant clinical manifestation of congenital dyserythropoietic anemia type 2. Acta Haematol 1985; 74: 178–80PubMedCrossRefGoogle Scholar
  13. 13.
    Bett JH, Wilkinson RK, Boyle CM. Iron overload associated with congenital pyruvate kinase deficiency and high dose ascorbic acid ingestion [letter]. Aust N Z J Med 1985; 15: 270PubMedCrossRefGoogle Scholar
  14. 14.
    Barton JC, Lee PL, West C, et al. Iron overload and prolonged ingestion of iron supplements: Clinical features and mutation analysis of hemochromatosis-associated genes in four cases. Am J Hematol 2006; 81: 760–7PubMedCrossRefGoogle Scholar
  15. 15.
    Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567–73PubMedCrossRefGoogle Scholar
  16. 16.
    Ceci A, Baiardi P, Cataprano M, et al. Risk factors for death in patients with β-thalassemia major: results of a case-control study. Haematologica 2006; 91: 1420–1PubMedGoogle Scholar
  17. 17.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005; 1054: 40–7PubMedCrossRefGoogle Scholar
  18. 18.
    Witte DL, Crosby WH, Edwards CQ, et al. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200CrossRefGoogle Scholar
  19. 19.
    Wu KH, Tsai FJ, Peng CT. Growth hormone (GH) deficiency in patients with beta-thalassemia major and the efficacy of recombinant GH treatment. Ann Hematol 2003; 82: 637–40PubMedCrossRefGoogle Scholar
  20. 20.
    De Sanctis V, Roos M, Gasser T, et al. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab 2006; 19: 471–80PubMedGoogle Scholar
  21. 21.
    Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129: 932–9PubMedGoogle Scholar
  22. 22.
    Carneiro AA, Vilela GR, Fernandes JB, et al. In vivo tissue characterization using magnetic techniques [abstract]. Neurol Clin Neurophysiol 2004; 2004: 85PubMedGoogle Scholar
  23. 23.
    Fischer R, Harmatz P, Nielsen P. Does liver biopsy overestimate liver iron concentration? Blood 2006; 108: 1775–6PubMedCrossRefGoogle Scholar
  24. 24.
    Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15–9PubMedCrossRefGoogle Scholar
  25. 25.
    Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005; 106: 1460–5PubMedCrossRefGoogle Scholar
  26. 26.
    Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol 2005; 123: 146–52PubMedCrossRefGoogle Scholar
  27. 27.
    St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855–61CrossRefGoogle Scholar
  28. 28.
    Kellner H, Zoller WG. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol 1992; 30: 779–83PubMedGoogle Scholar
  29. 29.
    de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med 1979; 300: 5–8PubMedCrossRefGoogle Scholar
  30. 30.
    Kaltwasser JP, Werner E, Schalk K, et al. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut 1998; 43: 699–704PubMedCrossRefGoogle Scholar
  31. 31.
    Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994; 83: 2329–33PubMedGoogle Scholar
  32. 32.
    Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood 1982; 60: 288–94PubMedGoogle Scholar
  33. 33.
    Hershko C, Link G, Konijn AM. Chelation therapy in iron overload. In: Barton JC, Edwards CQ, editors. Hemochromatosis: genetics, pathophysiology, diagnosis and treatment. Cambridge: Cambridge University Press, 2000: 339–54CrossRefGoogle Scholar
  34. 34.
    Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26–36PubMedCrossRefGoogle Scholar
  35. 35.
    Araujo A, Kosaryan M, MacDowell A, et al. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. Br J Haematol 1996; 93: 835–7PubMedCrossRefGoogle Scholar
  36. 36.
    Borgna-Pignatti C, Cohen A. Evaluation of a new method of administration of the iron chelating agent deferoxamine. J Pediatr 1997; 130: 86–8PubMedCrossRefGoogle Scholar
  37. 37.
    Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol 2002; 509: 91–125PubMedCrossRefGoogle Scholar
  38. 38.
    Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516–20PubMedCrossRefGoogle Scholar
  39. 39.
    Liu DY, Liu ZD, Hider RC. Oral iron chelators: development and application. Best Pract Res Clin Haematol 2002; 15: 369–84PubMedGoogle Scholar
  40. 40.
    Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 1995; 86: 2008–13PubMedGoogle Scholar
  41. 41.
    Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122: 305–10PubMedCrossRefGoogle Scholar
  42. 42.
    Agarwal MB, Gupte SS, Vasandani D, et al. Efficacy and safety of 1–2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload. J Assoc Physicians India 1991; 39: 669–72PubMedGoogle Scholar
  43. 43.
    Kontoghiorghes GJ, Aldouri MA, Sheppard L, et al. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987; I: 1294–5CrossRefGoogle Scholar
  44. 44.
    Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 1995; 332: 918–22PubMedCrossRefGoogle Scholar
  45. 45.
    al Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995; 89: 403–8CrossRefGoogle Scholar
  46. 46.
    Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583–7PubMedCrossRefGoogle Scholar
  47. 47.
    Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330–6PubMedCrossRefGoogle Scholar
  48. 48.
    Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339: 417–23PubMedCrossRefGoogle Scholar
  49. 49.
    Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100: 1566–9PubMedCrossRefGoogle Scholar
  50. 50.
    Barton JC. Deferasirox Novartis. Curr Opin Investig Drugs 2005; 6: 327–35PubMedGoogle Scholar
  51. 51.
    Cappellini MD. Iron-chelating therapy with the new oral agent ICL670 (Exjade). Best Pract Res Clin Haematol 2005; 18: 289–98PubMedCrossRefGoogle Scholar
  52. 52.
    Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565–72PubMedGoogle Scholar
  53. 53.
    Piga A, Galanello R, Foschini ML, et al. Once-daily treatment with the oral iron chelator ICL670 (Exjade): results of a phase II study in pediatric patients with beta-thalassemia major. Blood 2004, 104Google Scholar
  54. 54.
    Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873–80PubMedGoogle Scholar
  55. 55.
    Porter J, Vichinsky E, Rose C, et al. A phase II study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various transfusion-dependent anemias and iron overload [abstract]. Blood 2004; 104: 872aGoogle Scholar
  56. 56.
    Vanorden HE, Hagemann TM. Deferasirox: an oral agent for chronic iron overload. Ann Pharmacother 2006; 40: 1110–7PubMedCrossRefGoogle Scholar
  57. 57.
    Glickstein H, El RB, Shvartsman M, et al. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005; 106: 3242–50PubMedCrossRefGoogle Scholar
  58. 58.
    Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006; 108: 3195–203PubMedCrossRefGoogle Scholar
  59. 59.
    Piga A, Galanello R, Cappelini MD, et al. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy [abstract]. Blood 2002; 100: 5aGoogle Scholar
  60. 60.
    Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597–602PubMedCrossRefGoogle Scholar
  61. 61.
    Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455–62PubMedCrossRefGoogle Scholar
  62. 62.
    Bomford A, Williams R. Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med 1976; 45: 611–23PubMedGoogle Scholar
  63. 63.
    McLaren CE, Barton JC, Adams PC, et al. Hemochromatosis and Iron Overload Screening (HEIRS) study design for an evaluation of 100,000 primary care-based adults. Am J Med Sci 2003; 325: 53–62PubMedCrossRefGoogle Scholar
  64. 64.
    Bolan CD, Conry-Cantilena C, Mason G, et al. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001; 41: 819–27PubMedCrossRefGoogle Scholar
  65. 65.
    Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003; 98: 2072–7PubMedCrossRefGoogle Scholar
  66. 66.
    Conte D, Mandelli C, Cesana M, et al. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis: report of 14 cases. Int J Artif Organs 1989; 12: 59–62PubMedGoogle Scholar
  67. 67.
    Fraquelli M, Mandelli C, Cesarini L, et al. Survival and development of neoplasms in 56 patients with idiopathic hemochromatosis [in Italian]. Ann Ital Med Int 1992; 7: 26–9PubMedGoogle Scholar
  68. 68.
    Kohan A, Niborski R, Daruich J, et al. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2000; 79: 40–5PubMedCrossRefGoogle Scholar
  69. 69.
    Mariani R, Pelucchi S, Perseghin P, et al. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005; 90: 717–8PubMedGoogle Scholar
  70. 70.
    Cesana M, Mandelli C, Tiribelli C, et al. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine. Am J Gastroenterol 1989; 84: 150–2PubMedGoogle Scholar
  71. 71.
    Fabio G, Minonzio F, Delbini P, et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by severe type of juvenile hemochromatosis (JH). Blood 2007; 109: 362–4PubMedCrossRefGoogle Scholar
  72. 72.
    Wohler F. The treatment of haemochromatosis with desferrioxamine. Acta Haematol 1963; 30: 65–87CrossRefGoogle Scholar
  73. 73.
    Speight AN, Cliff J. Iron storage disease of the liver in Dar es Salaam: a preliminary report on venesection therapy. East Afr Med J 1974; 51: 895–902PubMedGoogle Scholar
  74. 74.
    Kattamis A, Papassotiriou I, Palaiologou D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006; 91: 809–12PubMedGoogle Scholar
  75. 75.
    Efthimiadis GK, Hassapopoulou HP, Tsikaderis DD, et al. Survival in thalassaemia major patients. Circ J 2006; 70: 1037–42PubMedCrossRefGoogle Scholar
  76. 76.
    Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8: 543–7PubMedCrossRefGoogle Scholar
  77. 77.
    Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733–7PubMedCrossRefGoogle Scholar
  78. 78.
    Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124: 114–7PubMedCrossRefGoogle Scholar
  79. 79.
    Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171–9PubMedCrossRefGoogle Scholar
  80. 80.
    Anderson LJ, Westwood MA, Prescott E, et al. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 2006; 115: 106–8PubMedCrossRefGoogle Scholar
  81. 81.
    Aldouri MA, Wonke B, Hoffbrand AV, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84: 113–7PubMedCrossRefGoogle Scholar
  82. 82.
    Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574–8PubMedCrossRefGoogle Scholar
  83. 83.
    Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051–2PubMedCrossRefGoogle Scholar
  84. 84.
    Piga A, Gaglioti C, Fogliacco E, et al. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489–96PubMedGoogle Scholar
  85. 85.
    Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28: 196–208PubMedCrossRefGoogle Scholar
  86. 86.
    Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738–44PubMedCrossRefGoogle Scholar
  87. 87.
    Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17–24PubMedCrossRefGoogle Scholar
  88. 88.
    Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121: 938–48PubMedCrossRefGoogle Scholar
  89. 89.
    Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361–4PubMedCrossRefGoogle Scholar
  90. 90.
    Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90: 1309–14PubMedGoogle Scholar
  91. 91.
    D’Angelo E, Mirra N, Rocca A, et al. Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia. J Pediatr Hematol Oncol 2004; 26: 451–3PubMedCrossRefGoogle Scholar
  92. 92.
    Kolnagou A, Kontoghiorghes GJ. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Hemoglobin 2006; 30: 239–49Google Scholar
  93. 93.
    Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91: 1241–3PubMedGoogle Scholar
  94. 94.
    Wu KH, Chang JS, Tsai CH, et al. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004; 83: 471–3PubMedCrossRefGoogle Scholar
  95. 95.
    Tavecchia L, Masera N, Russo P, et al. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica 2006; 91: ECR19PubMedGoogle Scholar
  96. 96.
    Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus: trends and risk factors over the period 1980–2004. Haematologica 2006; 91: 1187–92PubMedGoogle Scholar
  97. 97.
    Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992; 79: 2741–8PubMedGoogle Scholar
  98. 98.
    Kearney SL, Nemeth E, Neufeld EJ, et al. Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 2007; 48: 57–63PubMedCrossRefGoogle Scholar
  99. 99.
    Barton JC, Lee PL, Bertoli LF, et al. Iron overload in an African American woman with SS hemoglobinopathy and a promoter mutation in the X-linked erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Blood Cells Mol Dis 2005; 34: 226–8PubMedCrossRefGoogle Scholar
  100. 100.
    Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91: 288–94PubMedGoogle Scholar
  101. 101.
    Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5–11PubMedCrossRefGoogle Scholar
  102. 102.
    Adams RJ, Brambilla DJ, Granger S, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004; 103: 3689–94PubMedCrossRefGoogle Scholar
  103. 103.
    Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006; 108: 847–52PubMedCrossRefGoogle Scholar
  104. 104.
    Darbari DS, Kple-Faget P, Kwagyan J, et al. Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006; 81: 858–63PubMedCrossRefGoogle Scholar
  105. 105.
    Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38: 30–6PubMedCrossRefGoogle Scholar
  106. 106.
    Adams DM, Schultz WH, Ware RE, et al. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol 1996; 18: 46–50PubMedCrossRefGoogle Scholar
  107. 107.
    Hartwig D, Schlager F, Bucsky P, et al. Successful long-term erythrocytapheresis therapy in a patient with symptomatic sickle-cell disease using an arterio-venous fistula. Transfus Med 2002; 12: 75–7PubMedCrossRefGoogle Scholar
  108. 108.
    Hilliard LM, Williams BF, Lounsbury AE, et al. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 1998; 59: 28–35PubMedCrossRefGoogle Scholar
  109. 109.
    Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83: 1136–42PubMedGoogle Scholar
  110. 110.
    Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 1999; 14: 122–5PubMedCrossRefGoogle Scholar
  111. 111.
    Raj AB, Condurache T, Bertolone S, et al. Quantitative assessment of ventricular function in sickle cell disease: effect of long-term erythrocytapheresis. Pediatr Blood Cancer 2005; 45: 976–81PubMedCrossRefGoogle Scholar
  112. 112.
    Cohen A, Schwartz E. Excretion of iron in response to deferoxamine in sickle cell anemia. J Pediatr 1978; 92: 659–62PubMedCrossRefGoogle Scholar
  113. 113.
    Pippard MJ. Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobinopathies. Acta Haematol 1987; 78: 206–11PubMedCrossRefGoogle Scholar
  114. 114.
    Treadwell MJ, Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin Hematol 2001; 38: 77–84PubMedCrossRefGoogle Scholar
  115. 115.
    Treadwell MJ, Law AW, Sung J, et al. Barriers to adherence of deferoxamine usage in sickle cell disease. Pediatr Blood Cancer 2005; 44: 500–7PubMedCrossRefGoogle Scholar
  116. 116.
    Shalev O, Hileti D, Nortey P, et al. Transport of 14C-deferiprone in normal, thalassaemic and sickle red blood cells. Br J Haematol 1999; 105: 1081–3PubMedCrossRefGoogle Scholar
  117. 117.
    Voskaridou E, Douskou M, Terpos E, et al. Deferiprone as an oral iron chelator in sickle cell disease. Ann Hematol 2005; 84: 434–40PubMedCrossRefGoogle Scholar
  118. 118.
    Okpala I. Investigational agents for sickle cell disease. Expert Opin Investig Drugs 2006; 15: 833–42PubMedCrossRefGoogle Scholar
  119. 119.
    Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87: 743–5PubMedCrossRefGoogle Scholar
  120. 120.
    List AF. New approaches to the treatment of myelodysplasia. Oncologist 2002; 7 Suppl. 1: 39–49PubMedCrossRefGoogle Scholar
  121. 121.
    Bowen D. What is ineffective erythropoiesis in myelodysplastic syndromes? Leuk Lymphoma 1995; 18: 243–7PubMedCrossRefGoogle Scholar
  122. 122.
    Rose C, Cambier N, Mahieu M, et al. Iron overload and myelodysplastic syndromes [in French]. Transfus Clin Biol 2001; 8: 422–32PubMedCrossRefGoogle Scholar
  123. 123.
    Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–603PubMedCrossRefGoogle Scholar
  124. 124.
    Barton JC, Bertoli LF, Acton RT. HFE C282Y and H63D in adults with malignancies in a community medical oncology practice. BMC Cancer 2004; 4: 6PubMedCrossRefGoogle Scholar
  125. 125.
    Varkonyi J, Tarkovacs G, Karadi I, et al. High incidence of hemochromatosis gene mutations in the myelodysplastic syndrome: the Budapest Study on 50 patients. Acta Haematol 2003; 109: 64–7PubMedCrossRefGoogle Scholar
  126. 126.
    Hannuksela J, Savolainen ER, Koistinen P, et al. Prevalence of HFE genotypes, C282Y and H63D, in patients with hematologic disorders. Haematologica 2002; 87: 131–5PubMedGoogle Scholar
  127. 127.
    Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4: 58–77PubMedGoogle Scholar
  128. 128.
    Borgna-Pignatti C, Franchini M, Gandini G, et al. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. Haematologica 1998; 83: 788–90PubMedGoogle Scholar
  129. 129.
    Del Rio GJ, Fernandez LC, Batlle Fonrodona FJ. Desferrioxamine in the treatment of myelodysplastic syndromes. Haematologica 1997; 82: 639–40Google Scholar
  130. 130.
    Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288–99PubMedCrossRefGoogle Scholar
  131. 131.
    Jiang Y, Xue ZH, Shen WZ, et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 2005; 19: 1239–47PubMedCrossRefGoogle Scholar
  132. 132.
    Leardi A, Caraglia M, Selleri C, et al. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br J Haematol 1998; 102: 746–52PubMedCrossRefGoogle Scholar
  133. 133.
    Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992; 80: 121–4PubMedCrossRefGoogle Scholar
  134. 134.
    Marsh JH, Hundert M, Schulman P. Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 1990; 76: 148–9PubMedCrossRefGoogle Scholar
  135. 135.
    Meo A, Ruggeri A, La Rosa MA, et al. Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation. Hemoglobin 2006; 30: 131–7PubMedCrossRefGoogle Scholar
  136. 136.
    Cermak J. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy. Hemoglobin 2006; 30: 105–12PubMedCrossRefGoogle Scholar
  137. 137.
    Kersten MJ, Lange R, Smeets ME, et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Hematol 1996; 73: 247–52PubMedCrossRefGoogle Scholar
  138. 138.
    al Refaie FN, Wonke B, Hoffbrand AV. Deferiprone-associated myelotoxicity. Eur J Haematol 1994; 53: 298–301CrossRefGoogle Scholar
  139. 139.
    Gattermann N, Cazzola M, Greenberg P, et al. The efficacy and tolerability of ICL670, a once-daily oral iron chelator, in patients with myelodysplastic syndromes (MDS) and iron overload. Leuk Res 2005; 29 Suppl. 1: S76Google Scholar
  140. 140.
    Angelucci E, Muretto P, Lucarelli G, et al. Treatment of iron overload in the ‘ex-thalassemic’: report from the phlebotomy program. Ann N Y Acad Sci 1998; 850: 288–93PubMedCrossRefGoogle Scholar
  141. 141.
    Barton JC, Lee PL. Disparate phenotypic expression of ALAS2 R452H (nt 1407 G → A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells Mol Dis 2006; 36: 342–6PubMedCrossRefGoogle Scholar
  142. 142.
    Caines AE, Kpodonu J, Massad MG, et al. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant 2005; 24: 486–8PubMedCrossRefGoogle Scholar
  143. 143.
    Barton JC, Edwards CQ, Bertoli LF, et al. Iron overload in African Americans. Am J Med 1995; 99: 616–23PubMedCrossRefGoogle Scholar
  144. 144.
    Hoffbrand AV, Bartlett AN, Veys PA, et al. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial [letter]. Lancet 1989; II: 457CrossRefGoogle Scholar
  145. 145.
    Alter BP. Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation [letter]. Lancet 1990; 335: 970PubMedCrossRefGoogle Scholar
  146. 146.
    Kontoghiorghes GJ, Bartlett AN, Sheppard L, et al. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes. Arzneimittelforschung 1995; 45: 65–9PubMedGoogle Scholar
  147. 147.
    Donovan JM, Plone M, Dagher R, et al. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci 2005; 1054: 492–4PubMedCrossRefGoogle Scholar
  148. 148.
    Hider RC, Zhou T. The design of orally active iron chelators. Ann N Y Acad Sci 2005; 1054: 141–54PubMedCrossRefGoogle Scholar
  149. 149.
    Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions: comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin 2006; 30: 329–47PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Suite G-105 Ambulatory Care CenterSouthern Iron Disorders CenterBirminghamUSA

Personalised recommendations